College Hill Appointed by Abraxis to support its launch of ABRAXANE® into Europe

03.12.08 - 22:03 ... source : College Hill

... London, 3rd December 2008... College Hill's Life Sciences team has been appointed by Abraxis Bioscience (NASDAQ: ABII) to support the European launch of its product ABRAXANE®, with initial focus in the UK and Germany. College Hill's remit includes both corporate and product-based public and media relations. Abraxis is a fully integrated biotechnology company focused on delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. With headquarters in Los Angeles, California, USA, Abraxis also has operations in Canada, China, Switzerland and the UK. Its lead product ABRAXANE® is the world's first and only albumin bound nanoparticle chemotherapeutic compound which is based on its proprietary tumour targeting system known as the nab™ platform. ABRAXANE® has been approve ...» Next (HTML)